Corbus Pharmaceuticals Holdings, Inc.
CRBPHealthcare|Biotechnology|US
$3.07
+0.21 (+7.34%)
DCF Value
$1.97
Tangible Book / Share
$5.27
Cash / Share
$6.08
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07768189 A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal Carcinoma (OPC) | P3 | Recruiting | 260 | RCT, Single-blind | CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel |
| NCT06603844 First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Solid Tumor | P1P2 | Recruiting | 156 | Open-label | CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody |
| NCT06265727 A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Solid Tumor, Adult | P1P2 | Recruiting | 348 | RCT, Open-label | CRB-701, Anti-PD-1 |
| NCT03813160 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis | Dermatomyositis | P3 | Completed | 176 | RCT, Double-blind | Lenabasum 20 mg, Lenabasum 5 mg, Placebo |
| NCT03398837 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis | Diffuse Cutaneous Systemic Sclerosis | P3 | Terminated | 365 | RCT, Double-blind | Lenabasum 5 mg, Lenabasum 20 mg |
| NCT02465450 Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis | Cystic Fibrosis | P2 | Completed | 85 | RCT, Double-blind | JBT-101 (lenabasum) |
| NCT03451045 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis | Cystic Fibrosis | P2 | Completed | 447 | RCT, Double-blind | Lenabasum 20 mg, Lenabasum 5 mg |
| NCT02465437 Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis | Diffuse Cutaneous Systemic Sclerosis | P2 | Terminated | 42 | RCT, Double-blind | JBT-101, Placebo, Part B Open-Label Extension |
| NCT03093402 JBT-101 in Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus, SLE | P2 | Completed | 109 | RCT, Double-blind | JBT-101, Placebo |
| NCT02466243 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis | Dermatomyositis | P2 | Terminated | 22 | RCT, Double-blind | JBT-101, Placebo |
| NCT07310901 A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity | Obese But Otherwise Healthy Participants | P1 | Completed | 254 | RCT, Double-blind | CRB-913, Placebo |